Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314145 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX
A Phase 3 study of Japanese Encephalitis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
- 10
- Study locations
NCT00314145 is a Phase 3 study of Japanese Encephalitis that has completed, run by Sanofi. The registered enrollment target is 820 participants. The trial reports 10 study locations across 6 states.
The verdict
NCT00314145, a Phase 3 study of Japanese Encephalitis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
Conditions Studied
Interventions
- BIOLOGICAL ChimeriVax™-JE
- BIOLOGICAL JE-VAX®
Study Locations (10)
Other
- - Adelaide
- - Melbourne
- - New South Wales
- - Queensland
- - Victoria
Illinois
- - Chicago
Kansas
- - Shawnee Mission
Montana
- - Missoula
Texas
- - Dallas
Washington
- - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314145
The ClinicalTrials.gov registry entry for NCT00314145 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Japanese Encephalitis appearing as the primary indexed condition, and to 2 interventions - of which ChimeriVax™-JE is the first listed.
NCT00314145 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Other, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT00314145 about?
NCT00314145 is a clinical study titled "A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX". The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
What is the current status of trial NCT00314145?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2005-11. Estimated completion is 2006-11.
What conditions does trial NCT00314145 study?
This clinical trial studies the following conditions: Japanese Encephalitis.
What interventions are being tested in trial NCT00314145?
The interventions under investigation include: ChimeriVax™-JE (BIOLOGICAL), JE-VAX® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00314145?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00314145 being conducted?
This trial has 10 study locations across Illinois, Kansas, Montana, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Japanese Encephalitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.